Prothena Corp PLC (0PT.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 08:15PM CEST
| Previous close | 14.70 |
| Open | 15.20 |
| Bid | 15.30 x 300000 |
| Ask | 15.40 x 300000 |
| Day's range | 15.10 - 15.50 |
| 52-week range | 14.60 - 49.20 |
| Volume | |
| Avg. volume | 7 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 04 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksEli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
Business WireProthena to Participate in Upcoming Healthcare Conferences
DUBLIN, August 29, 2024--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in September 2024.
ZacksWhat Makes Prothena (PRTA) a New Buy Stock
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2024 Yahoo. All rights reserved.